



(11) **EP 3 710 005 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54, 73
- (48) Corrigendum issued on:
14.06.2023 Bulletin 2023/24
- (45) Date of publication and mention of the grant of the patent:
24.08.2022 Bulletin 2022/34
- (21) Application number: **18879252.7**
- (22) Date of filing: **16.11.2018**
- (51) International Patent Classification (IPC):
C07D 487/04^(2006.01) A61K 31/5025^(2006.01)
A61P 35/00^(2006.01) A61P 35/02^(2006.01)
- (52) Cooperative Patent Classification (CPC):
(C-Sets available)
C07D 487/04; A61K 9/1271; A61K 31/5025;
A61K 33/243; A61K 45/06; A61P 35/00;
A61P 35/02 (Cont.)
- (86) International application number:
PCT/US2018/061400
- (87) International publication number:
WO 2019/099755 (23.05.2019 Gazette 2019/21)

(54) **SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER**

SUBSTITUIERTE PYRROLO[2,1,-ALPHA]PHTHALAZINE- UND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS

PYRROLO[2,1,-ALPHA]PHTHALAZINES ET BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES SUBSTITUÉS et LEURS UTILSATIONS DANS LE TRAITEMENT DU CANCER

- (84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
- (30) Priority: **17.11.2017 US 201762587484 P**
- (43) Date of publication of application:
23.09.2020 Bulletin 2020/39
- (73) Proprietor: **Academia Sinica**
Nankang, Taipei 115 (TW)
- (72) Inventors:
• **SU, Tsann-long**
Amawalk
NY 10501 (US)
• **LEE, Te-chang**
Taipei 11521 (TW)
• **CHEN, Tai-lin**
New Taipei City 220 (TW)
- (74) Representative: **Lang, Christian**
LangPatent Anwaltskanzlei IP Law Firm
Ingolstädter Straße 5
80807 München (DE)
- (56) References cited:
WO-A1-2016/144847 WO-A2-03/082208
US-A- 4 960 775 US-A1- 2004 209 886
US-A1- 2005 070 545 US-A1- 2010 184 771
US-B2- 7 153 854
- **LEE et al.: "Combination of Bifunctional Alkylating Agent and Arsenic Trioxide synergistically Suppresses the Growth of Drug-Resistant Tumor Cells", NEOPLASIA, vol. 12, no. 5, 2010, pages 376-387, XP055610931,**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 710 005 B8

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets

A61K 31/5025, A61K 2300/00;

A61K 33/243, A61K 2300/00